Sezai, A.; Tanaka, A.; Imai, T.; Kida, K.; Sekino, H.; Murohara, T.; Sata, M.; Suzuki, N.; Node, K., on behalf of CANDLE Trial Investigators.
Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial. Biomedicines 2022, 10, 1656.
https://doi.org/10.3390/biomedicines10071656
AMA Style
Sezai A, Tanaka A, Imai T, Kida K, Sekino H, Murohara T, Sata M, Suzuki N, Node K on behalf of CANDLE Trial Investigators.
Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial. Biomedicines. 2022; 10(7):1656.
https://doi.org/10.3390/biomedicines10071656
Chicago/Turabian Style
Sezai, Akira, Atsushi Tanaka, Takumi Imai, Keisuke Kida, Hisakuni Sekino, Toyoaki Murohara, Masataka Sata, Norio Suzuki, and Koichi Node on behalf of CANDLE Trial Investigators.
2022. "Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial" Biomedicines 10, no. 7: 1656.
https://doi.org/10.3390/biomedicines10071656
APA Style
Sezai, A., Tanaka, A., Imai, T., Kida, K., Sekino, H., Murohara, T., Sata, M., Suzuki, N., & Node, K., on behalf of CANDLE Trial Investigators.
(2022). Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial. Biomedicines, 10(7), 1656.
https://doi.org/10.3390/biomedicines10071656
